Celldex

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Celldex and other ETFs, options, and stocks.

About CLDX

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. 

CEO
Anthony S. Marucci
CEOAnthony S. Marucci
Employees
186
Employees186
Headquarters
Hampton, New Jersey
HeadquartersHampton, New Jersey
Founded
1983
Founded1983
Employees
186
Employees186

CLDX Key Statistics

Market cap
1.72B
Market cap1.72B
Price-Earnings ratio
-7.66
Price-Earnings ratio-7.66
Dividend yield
Dividend yield
Average volume
946.96K
Average volume946.96K
High today
$26.15
High today$26.15
Low today
$24.79
Low today$24.79
Open price
$24.93
Open price$24.93
Volume
607.67K
Volume607.67K
52 Week high
$29.05
52 Week high$29.05
52 Week low
$14.40
52 Week low$14.40

Stock Snapshot

Celldex(CLDX) stock is priced at $26.15, giving the company a market capitalization of 1.72B. It carries a P/E multiple of -7.66.

As of 2025-11-22, Celldex(CLDX) stock has fluctuated between $24.79 and $26.15. The current price stands at $26.15, placing the stock +5.5% above today's low and 0.0% off the high.

The Celldex(CLDX)'s current trading volume is 607.67K, compared to an average daily volume of 946.96K.

In the last year, Celldex(CLDX) shares hit a 52-week high of $29.05 and a 52-week low of $14.40.

In the last year, Celldex(CLDX) shares hit a 52-week high of $29.05 and a 52-week low of $14.40.

CLDX News

Simply Wall St 11h
How Investors May Respond To Celldex Therapeutics Leadership Change and Widening Third-Quarter Losses

Celldex Therapeutics recently reported third-quarter 2025 results, including a larger net loss of US$67.04 million and a loss per share of US$1.01, alongside a...

How Investors May Respond To Celldex Therapeutics Leadership Change and Widening Third-Quarter Losses
Simply Wall St 3d
Celldex Therapeutics: Assessing Valuation After Recent Revenue Growth and Share Price Swings

Celldex Therapeutics (CLDX) shares have experienced some short-term swings lately, and investors may be wondering what is behind these moves. Over the past mont...

Celldex Therapeutics: Assessing Valuation After Recent Revenue Growth and Share Price Swings

Analyst ratings

81%

of 16 ratings
Buy
81.3%
Hold
12.5%
Sell
6.3%

People also own

Based on the portfolios of people who own CLDX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.